UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Cancer Immunology, Immunotherapy, 2020-12, Vol.69 (12), p.2589-2598

2020

Link zum Volltext

Verfügbarkeit prüfen

Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases

Cancer research (Chicago, Ill.), 2012-08, Vol.72 (16), p.3997-4007

2012

Link zum Volltext

Verfügbarkeit prüfen

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Journal of translational medicine, 2019-09, Vol.17 (1), p.303-303, Article 303

2019

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for the treatment of uveal melanoma: A case series

Rare tumors, 2020, Vol.12, p.203636132097198-2036361320971983

2020

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and management of COVID toes in outpatients: a case report

Journal of medical case reports, 2024-06, Vol.18 (1), p.307-5, Article 307

2024

Link zum Volltext

Verfügbarkeit prüfen

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Cancers, 2021-01, Vol.13 (2), p.168

2021

Link zum Volltext

Verfügbarkeit prüfen

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

Cancers, 2022-01, Vol.14 (3), p.682

2022

Link zum Volltext

Verfügbarkeit prüfen

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse

Cancers, 2021-01, Vol.13 (3), p.442

2021

Link zum Volltext

Verfügbarkeit prüfen

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

The lancet oncology, 2017-04, Vol.18 (4), p.464-472

2017

Link zum Volltext

Verfügbarkeit prüfen

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure

Melanoma research, 2015-02, Vol.25 (1), p.68-74

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma

International journal of radiation oncology, biology, physics, 2019-07, Vol.104 (4), p.828-835

2019

Link zum Volltext

Verfügbarkeit prüfen

Allergic contact dermatitis from pentylene glycol in ‘hypoallergenic’ eye cosmetics

Contact dermatitis, 2023-01, Vol.88 (1), p.73-75

2023

Link zum Volltext

Verfügbarkeit prüfen

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases

Case reports in oncological medicine, 2015-01, Vol.2015, p.472037-5

2015

Link zum Volltext

Verfügbarkeit prüfen

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Journal of translational medicine, 2016-04, Vol.14 (95), p.95-95, Article 95

2016

Link zum Volltext

Verfügbarkeit prüfen

Allergic contact dermatitis from pantolactone and dexpanthenol in wound healing creams

Contact dermatitis, 2022-11, Vol.87 (5), p.468-471

2022

Link zum Volltext

Verfügbarkeit prüfen

Allergic contact dermatitis from a skin‐calming cream containing hydroxyphenyl propamidobenzoic acid

Contact dermatitis, 2023-01, Vol.88 (1), p.68-70

2023

Link zum Volltext

Verfügbarkeit prüfen

A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9585-9585

2019

Link zum Volltext

Verfügbarkeit prüfen

It is not always chlorhexidine: Identification of benzoxonium chloride and lauramine oxide as culprit allergens in a popular antiseptic in Switzerland

Contact dermatitis, 2023-10, Vol.89 (4), p.284-289

2023

Link zum Volltext

Verfügbarkeit prüfen

Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22041-e22041

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition

Blood advances, 2018-08, Vol.2 (16), p.2156-2158

2018

Link zum Volltext

Verfügbarkeit prüfen

Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series

Journal of the European Academy of Dermatology and Venereology, 2024-02

2024

Link zum Volltext

Verfügbarkeit prüfen

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib

Melanoma research, 2015-12, Vol.25 (6), p.550-554

2015

Link zum Volltext

Verfügbarkeit prüfen

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy

Melanoma research, 2018-02, Vol.28 (1), p.65-70

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy

The cancer journal (Sudbury, Mass.), 2011-09, Vol.17 (5), p.325

2011

Link zum Volltext

Verfügbarkeit prüfen

ctDNA as a noninvasive monitoring tool in metastatic melanoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9548-9548

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(36)
Berichte
(3)

Sprache

Englisch
(39)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Humans
(15)
Oncology
(15)
Dermatology
(11)
Melanoma
(11)
Immunotherapy
(9)
Female
(8)
Medicine, Research & Experimental
(8)
Middle Aged
(8)
Research & Experimental Medicine
(8)
Male
(7)
Melanoma - Genetics
(7)
Metastasis
(7)
Patients
(7)
Proto-Oncogene Proteins B-Raf - Genetics
(7)
Adult
(6)
Melanoma - Pathology
(6)
Skin Neoplasms - Genetics
(6)
Skin Neoplasms - Pathology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Pembrolizumab for the treatment of uveal melanoma: A case series

Diagnosis and management of COVID toes in outpatients: a case report

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma

Allergic contact dermatitis from pentylene glycol in ‘hypoallergenic’ eye cosmetics

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Allergic contact dermatitis from pantolactone and dexpanthenol in wound healing creams

Allergic contact dermatitis from a skin‐calming cream containing hydroxyphenyl propamidobenzoic acid

A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM)

It is not always chlorhexidine: Identification of benzoxonium chloride and lauramine oxide as culprit allergens in a popular antiseptic in Switzerland

Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition

Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy

ctDNA as a noninvasive monitoring tool in metastatic melanoma

Suchergebnisse filtern